BUZZ-<a href="https://laohu8.com/S/CYTK">Cytokinetics</a> rises after FDA approves co's drug for rare heart disease ** Shares of drugmaker Cytokinetics CYTK.O rise 2% to $63.93 premarket
** The U.S. Food and Drug Administration on Friday approved Cytokinetics' oral drug to treat a rare heart condition called obstructive hypertrophic cardiomyopathy
** The keenly watched drug, branded as Myqorzo, will compete with Bristol Myers' BMY.N Camzyos
** "We believe BMY's Camzyos will maintain first-in-class market share advantage vs. CYTK's Myqorzo in oHCM," said Guggenheim Partners analyst Seamus Fernandez
** As of last close, CYTK stock was up 33.3% YTD
(Reporting by Padmanabhan Ananthan)
((Padmanabhan.Ananthan@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments